Antiplatelet Drugs Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH620 | Last Updated On: Nov 03 2022 | Available Formats

> Antiplatelet Drugs Market Expected to reach a high CAGR of 9.68% by 2029: DataM Intelligence

Antiplatelet Drugs Market is segmented By Product type (Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor, Abciximab, others), By Mode of Administration (Oral, Intravenous), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Antiplatelet Drugs Market was valued at US$ 1,955.29 million in 2021 and is estimated to reach US$ 4,307.75 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).      

Antiplatelet Drugs Market 



Market CAGR


Segments Covered

 By Antiplatelet Drug Class, By Route of Administration, By Application, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Antiplatelet Drugs are a group of medicines that prevent blood clotting. Antiplatelet medications are used to avoid coronary artery disease, heart attack, angina (chest pain), Stroke and Transient Ischemic Attacks (TIAs) and peripheral artery disease. Antiplatelet drugs are also used post surgeries of the stent, bypass surgery, and others.

Market Dynamics

The increasing demand for these antiplatelet drugs, the rising incidence of heart attack, atrial fibrillation and peripheral vascular disease, the increasing research and development expenditure and growth in studies and novel product launches are expected to drive market growth.

The increasing novel product launches and demand for antiplatelet drugs will drive market growth. 

The global market for antiplatelet drugs is primarily driven by the healthcare industry's demand for antiplatelet drugs due to increasing chronic disorders such as angina, atrial fibrillation and coronary artery disease. Studies are being conducted on novel antiplatelet drugs to examine their safety, efficacy and other capabilities. For instance, in May 2022, Johnson and Johnson announced that its results from XARELTO (rivaroxaban), combined with the acetylsalicylic acid (XATOA) registry, were published in the European Heart Journal of the European Society of Cardiology. This study supports XARELTO’s dual pathway inhibition role in coronary artery disease patients.

Various novel technological advancements are taking place, and the number of the latest, innovative product launches is increasing, leading to the high demand for these antiplatelet drugs.  For instance, In Feb 2021, Sanofi announced the approval of additional indication for Plavix (Clopidogrel) by the European Commission. This new indication includes using a combination of Plavix and aspirin for patients with minor Ischemia Stroke and high-risk Transient Ischemia Attack within 1 day of any of the above events. Under this novel indication, the usage can be continued for 21 days, subsequently, long-term antiplatelet therapy (single).

Increasing risks and side effects associated with antiplatelet drugs will hamper the market’s growth.  

However, increasing bleeding risks in highly complicated surgeries is a major drawback hampering the market's growth. The misconception of antiplatelet drugs with blood-thinning drugs is also a considerable restraint for market growth. Side effects such as nausea, upset stomach, stomach pain, diarrhea, rash, and itching are also affecting the consumption of antiplatelet drugs in recent years.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The antiplatelet drugs market has experienced huge losses due to shifting all the attention to COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various collaborations and mergers are happening worldwide, boosting the market’s growth.  

Segment Analysis

The irreversible cyclooxygenase inhibitor segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The irreversible cyclooxygenase inhibitor segment is the highest market holder in the global antiplatelet drugs market. Cyclooxygenase inhibitors are medicines that are commonly used in treating syndromes related to chronic pain. They are included in the anti-inflammatory drug class. Aspirin is a non-selective cyclooxygenase inhibitor that irreversibly acetyls a residue of serine in the enzyme cyclooxygenase, also called platelet prostaglandin synthase. Thromboxane A2 is the predominant product of cyclooxygenase. It is used as a secondary treatment in various vascular events. According to an article published and updated in May 2022 by the National Centre of Biotechnology Information titled “Antiplatelet Medication,” Aspirin is an oral antiplatelet drug used commonly as it irreversibly inhibits the enzyme cyclooxygenase activity in the pathway of prostaglandin synthesis. The irreversible cyclooxygenase inhibitor dominates the market due to increased target diseases such as angina, atrial fibrillation, heart attack and peripheral vascular disease globally. According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements or research/ clinical trial studies are driving the market’s growth. For Instance, in Apr 2022, PhaseBio Pharmaceutical, a biopharma company, announced its results from clinical trial phase 2b of bentracimab in the American college of cardiology’s 71st annual scientific session.

Geographical Analysis

North America holds the largest market share of the global antiplatelet drugs market.

North America dominates the global antiplatelet drug market, primarily attributed to the rising prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease due to unhealthy lifestyles and changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America’s rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually.

Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market’s growth. Many key developments and technological advancements are taking place based in this region. For instance, in Nov 2020, Mylan N.V. and Upjohn, Pfizer business combined to form Viatris Inc. Viatris has manufacturing and commercializing experience with the capability of regulatory and medical commercialization to provide the patients with better quality medicines.

Competitive Landscape

The antiplatelet drugs market is highly competitive with local and global companies’ presence. AstraZeneca, Bayer Pharmaceuticals, Bristol-Myers Squibb Company, Boehringer Ingelheim Pharmaceuticals, Hoffmann La Roche, Viatris (Mylan), Teva pharmaceuticals, Merck & Co., Inc., Sanofi, Pfizer Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Aug 2022, Bristol Myers Squibb company announced the results of the AXIOMATIC-SSP phase 2 study investigating milvexian, an oral factor Xla inhibitor, under collaboration with Janssen Pharmaceuticals Inc., Johnson & Johnson company. This study shows a relative risk reduction of 30% in symptomatic recurrent ischemia strokes and its safety results compared to a placebo combined in acute non-cardioembolic ischemia stroke patients with background antiplatelet therapy. 



AstraZeneca is a science-led, bio-pharmaceutical company that researches, develops and markets prescription medicines. It was established in 1999 and is headquartered in Cambridge, United Kingdom.

­Product Portfolio:

Ticagrelor (Brilinta): Brilinta is an oral antiplatelet or blood-thinning drug that maintains the body’s blood flow and prevents blood clot formation. Minimizes the death rate in heart attack and cardiovascular disease.

The global antiplatelet drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.  

Trending Topics

Antiulcerant Drugs Market

Inhalable Drugs Market

Antifungal Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!